Oncology Expert Insights

Michael Dennis, MD, physician, Dana-Farber Cancer Institute; instructor, medicine, Harvard Medical School

Long-Term Data Underscore the Enduring Efficacy of PD-1 Inhibition in Nasopharyngeal Carcinoma: With Michael Dennis, MD

June 23rd 2025

Dr Dennis discusses guidelines for nasopharyngeal carcinoma management and data with first-line toripalimab plus chemotherapy in metastatic disease.

Kate Gasparini, PharmD, BCOP, BCPPS, pediatric oncology clinical pharmacy specialist, Memorial Sloan Kettering Cancer Center

Liquid Imatinib Formulation Expands Leukemia Treatment Options and Improves Treatment Adherence: With Kate Gasparini, PharmD, BCOP, BCPPS

ByKate Gasparini, PharmD, BCOP, BCPPS

June 17th 2025

Kate Gasparini, PharmD, BCOP, BCPPS, discusses the oral formulation of imatinib for pediatric and adult patients with leukemias and other malignancies.

The Expanding Role of AR Inhibition in mHSPC Management: With Alicia Morgans, MD, MPH

ByAlicia Morgans, MD, MPH, FASCO

June 16th 2025

Alicia Morgans, MD, MPH, details the evolving role of AR inhibitors in the mHSPC setting, including the recent expanded approval for darolutamide for this population.

T-DXd Plus Pertuzumab Could Redefine First-Line HER2+ Breast Cancer Management: With Paolo Tarantino, MD

ByPaolo Tarantino, MD

June 11th 2025

Paolo Tarantino, MD, discusses key updates in HER2-positive breast cancer presented at the 2025 ASCO Annual Meeting

Telisotuzumab Vedotin Shakes Up Management of Pretreated, c-MET–Overexpressing NSCLC: With Jonathan W. Goldman, MD

ByJonathan W. Goldman, MD

June 10th 2025

Jonathan W. Goldman, MD, discusses the role of telisotuzumab vedotin in c-MET protein–overexpressing, nonsquamous, EGFR wild-type NSCLC.

Elizabeth Mittendorf, MD, PhD, MHCM, Robert and Karen Hale Distinguished Chair in Surgical Oncology, vice chair, research, Department of Surgery, Brigham and Women's Hospital; co-leader, Breast Program, director, Breast Immuno-Oncology Program, Dana-Farber Brigham Cancer Center; co-leader, Parker Institute for Cancer Immunotherapy, Dana-Farber Cancer Institute; professor, surgery, Harvard Medical School

Collaborative Structural Reforms Represent a Way Forward for Oncology Innovations: With Elizabeth Mittendorf, MD, PhD, MHCM

ByElizabeth Mittendorf, MD, PhD, MHCM

June 9th 2025

Dr Mittendorf shares how ASCO plans to address the implications of federal research funding cuts and how structural reforms may bolster oncology progress.

Multidisciplinary Collaboration and Mentorship Lay the Foundation for a New Chapter of ASCO Leadership: With Elizabeth Mittendorf, MD, PhD, MHCM

ByElizabeth Mittendorf, MD, PhD, MHCM

June 2nd 2025

Dr Mittendorf discusses her priorities for advancing patient care and supporting up-and-coming oncology professionals during her 2026-2027 ASCO presidency.

Kanwarpal S. Kahlon, MD, associate clinical professor, medicine, UCLA School of Medicine

Eltrombopag Biosimilar Improves Accessibility for Immune Thrombocytopenia & Aplastic Anemia: With Kanwarpal S. Kahlon, MD

ByKanwarpal S. Kahlon, MD

May 22nd 2025

Dr Kahlon discusses the availability of the generic formulations of eltrombopag for patients with aplastic anemia and immune thrombocytopenia.

Michael J. Mauro, MD, attending physician, Memorial Sloan Kettering Cancer Center

Updated Nilotinib Formulation Improves Treatment Adherence in Ph+ CML: With Michael J. Mauro, MD

ByMichael J. Mauro, MD

May 19th 2025

Dr Mauro discusses ways that the newest formulation of nilotinib for Ph-positive CML addresses treatment adherence issues by reducing the need for fasting.

Shubham Pant, MD, MBBS, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center; Professor Timothy Elliott, Kidani Professor of Immuno-oncology, Nuffield Department of Medicine, the University of Oxford

Cancer Vaccines Shake Up Disease Management and Prevention Strategies: With Shubham Pant, MD, MBBS; and Professor Timothy Elliott

ByShubham Pant, MD, MBBS,Professor Timothy Elliott

May 15th 2025

Pant and Elliott discuss research seeking to extend the benefits of cancer vaccines as cancer management and prevention strategies.

Christopher L. Moertel, MD, professor, Pediatric Neuro-Oncology Fellowship Program director, Division of Pediatric Hematology/Oncology, faculty member, Department of Pediatrics, medical director, Pediatric Neuro-Oncology and Neurofibromatosis Programs, co-medical director, Katie Hageboeck Children’s Cancer Research Fund Clinic, clinical neuro-oncology leader, Brain Tumor Program, Kenneth and Betty Jayne Dahlberg Professor, University of Minnesota School of Medicine

MEK Inhibitors Expand the NF1-Associated PN Treatment Paradigm: With Christopher L. Moertel, MD

ByChristopher L. Moertel, MD

May 12th 2025

Dr Moertel discusses the expansion of the NF1-associated PN treatment paradigm to include the MEK inhibitors mirdametinib and selumetinib.

Anna C. Pavlick, BSN, MSc, DO, MBA, professor, medicine, Division of Hematology & Medical Oncology, Weill Cornell Medicine; founding director, Cutaneous Oncology Program, Weill Cornell Medicine and NewYork-Presbyterian

RP1 Plus Nivolumab Delivers Durable Responses in PD-1–Exposed Melanoma: With Anna C. Pavlick, BSN, MSc, DO, MBA

ByAnna C. Pavlick, DO

May 5th 2025

Dr Pavlick discusses the investigation of RP1 plus nivolumab in patients with advanced melanoma who have received prior immune checkpoint inhibition.

Nicole Lamanna, MD, hematologic oncologist, Herbert Irving Comprehensive Cancer Center, NewYork-Presbyterian/Columbia University Irving Medical Center

Disease Features and Treatment Intolerance Inform Pirtobrutinib Use in Pretreated CLL: With Nicole Lamanna, MD

ByNicole Lamanna, MD

April 28th 2025

Dr Lamanna discusses how disease progression, treatment intolerance, and prior therapy exposure inform the decision to initiate pirtobrutinib in CLL.

Daniel P. Petrylak, MD, professor, medicine (medical oncology) and urology, chief, Genitourinary Oncology, Yale School of Medicine and Smilow Cancer Hospital

Radioligand Therapy Advances Represent the Future of mCRPC Treatment: With Daniel P. Petrylak, MD

ByDaniel P. Petrylak, MD

April 24th 2025

Daniel P. Petrylak, MD, discusses the role of Lutetium Lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer.

Eric Christenson, MD, assistant professor, oncology, Johns Hopkins School of Medicine

Oncodetect MRD Test Aids Treatment Decision-Making in CRC and Other Solid Tumors: With Eric Christenson, MD

ByEric Christenson, MD

April 23rd 2025

Dr Christenson discusses the capabilities of the Oncodetect test, its clinical applications and pronostic value, and findings from the Alpha-CORRECT study.

Neal Shore, MD, FACS, medical director, Carolina Urologic Research Center

AR Pathway Inhibition Refines Prostate Cancer Treatment Strategies: With Neal Shore, MD, FACS

ByNeal Shore, MD, FACS

April 7th 2025

Dr Shore discusses advances that have been achieved with AR-directed agents in prostate cancer and considerations for the optimal use of these agents.

Chandler Park, MD Norton Cancer Institute

Comprehensive First-Line Bladder Cancer Treatment Begins With Careful Patient Selection: With Chandler Park, MD

ByChandler Park, MD, MSc, FACP

April 3rd 2025

Dr Park discusses the core regimens in the current frontline bladder cancer treatment paradigm and ways that this paradigm is expected to evolve.

David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center

Study Reveals Subgroups of Patients With RCC Who May Have Durable Responses to Immunotherapy: With David A. Braun, MD, PhD

ByDavid A. Braun, MD, PhD

March 27th 2025

Dr Braun discusses molecular factors that contribute to exceptional immune checkpoint inhibition responses among patients with renal cell carcinoma.

Xiuning Le, MD, PhD, associate professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center

Ivonescimab Improves PFS vs Pembrolizumab in Advanced PD-L1+ NSCLC: With Xiuning Le, MD, PhD

ByXiuning Le, MD, PhD

March 24th 2025

Xiuning Le, MD, PhD, discusses the HARMONi-2 trial of ivonescimab in patients with advanced PD-L1–positive non–small cell lung cancer.

Ibrahim T. Aldoss, MD, associate professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope; Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

Ponatinib Monotherapy Maintains MRD Negativity Following TKI/Chemotherapy Treatment in Ph+ ALL: With Ibrahim T. Aldoss, MD; and Elias Jabbour, MD

ByElias Jabbour, MD,Ibrahim Aldoss, MD

March 20th 2025

Drs Aldoss and Jabbour discuss an analysis of PhALLCON that support the use of ponatinib monotherapy after TKI/chemotherapy treatment in Ph-positive ALL.

Komal Jhaveri, MD, FACP, section head, Endocrine Therapy Research Program, clinical director, Early Drug Development Service, Patricia and James Cayne Chair for Junior Faculty, Memorial Sloan Kettering Cancer Center

Inavolisib Has a Favorable Risk-Benefit Profile for PIK3CA-Mutant, HR+ Metastatic Breast Cancer: With Komal Jhaveri, MD, FACP

ByKomal Jhaveri, MD, FACP

February 17th 2025

Dr Jhaveri discusses advice for managing inavolisib-related adverse effects and best practices for biomarker testing in patients with HR+ breast cancer.

Mark B. Geyer, MD, Adolescent and Young Adult Program leader, Adult Lymphoblastic Leukemia Program leader, Leukemia Service, chair, Quality Assessment, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center; Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

Ponatinib-Based Regimens Strengthen the Ph+ ALL Treatment Paradigm: With Mark B. Geyer, MD, and Elias Jabbour, MD

ByMark Geyer, MD,Elias Jabbour, MD

February 10th 2025

Drs Geyer and Jabbour discuss ponatinib in Ph+ ALL, data with this agent plus blinatumomab, and how the safety profile of ponatinib affects its use.

Heinz-Josef Lenz, MD, professor, medicine, Keck School of Medicine, University of Southern California (USC); J. Terrence Lanni Chair in Gastrointestinal Cancer Research, co-director, USC Center for Molecular Pathway and Drug Discovery, co-director, USC Norris Center for Cancer Drug Development

Advances in RAS-Mutant PDAC Management Emphasize the Importance of Biomarker Testing: With Heinz-Josef Lenz, MD

ByHeinz-Josef Lenz, MD

February 6th 2025

Dr Lenz discusses the prevalence of RAS mutations in PDAC, the importance of biomarker testing, and treatment advances for patients with this disease.

Elias Jabbour, MD, a professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center

Olverembatinib Research Signals a New Era of CP-CML Management: With Elias Jabbour, MD

ByElias Jabbour, MD

February 3rd 2025

Dr Jabbour discusses data that support the continued investigation of olverembatinib in patients with heavily pretreated chronic-phase CML.

How are Antibody-Drug Conjugates Shaping the NSCLC Treatment Paradigm? With David Gerber, MD

ByDavid Gerber, MD

January 27th 2025

Dr Gerber discusses the evolving role of ADCs in NSCLC, focusing on findings from clinical trials and considerations regarding the toxicity profile of TROP2-directed ADCs.

Ryan Cassaday, MD, associate professor, Clinical Research Division, Fred Hutchinson Cancer Center; associate professor, Division of Hematology and Oncology, University of Washington School of Medicine

Blinatumomab-Based Regimens Enhance and Refine the B-ALL Treatment Paradigm: With Ryan Cassaday, MD

ByRyan Cassaday, MD

January 23rd 2025

Ryan Cassaday, MD, discussed insights from trials investigating blinatumomab in patients with B-ALL that were reported at the 2024 ASH Annual Meeting.

Alexey Danilov, MD, PhD, Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director, Early Phase Therapeutics Program, the Systems Clinical Trials Office, co-director, Toni Stephenson Lymphoma Center, professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope; Susan M. O'Brien, MD, associate director, Clinical Science, Chao Family Comprehensive Cancer Center, medical director, Sue & Ralph Stern Center for Clinical Trials & Research, professor, medicine, Division of Hematology/Oncology, University of California Irvine School of Medicine

Explore the Evolving Role of BTK Inhibitors in CLL: With Alexey Danilov, MD, PhD; and Susan M. O'Brien, MD

ByAlexey V. Danilov, MD, PhD,Susan M. O'Brien MD

December 31st 2024

Drs Danilov and O'Brien discuss updates with acalabrutinib, zanubrutinib, and pirtobrutinib in CLL that were presented at the 2024 ASH Annual Meeting.

The Evolving Role of ctDNA in Guiding Adjuvant Chemotherapy Decisions in CRC: Insights from Stacey A. Cohen, MD

ByStacey A. Cohen, MD

December 26th 2024

Stacey A. Cohen, MD, discusses insights into the evolving role of circulating tumor DNA in clinical decision-making for patients with colorectal cancer.

Exploring Luspatercept's Role in Anemia Management for Lower-Risk MDS: Insights From Dr. Jorge Cortes

ByJorge Cortes, MD

December 25th 2024

Jorge Cortes, MD discusses the FDA approval of luspatercept-aamt has influenced first-line MDS management.

Onyee Chan, MD, hematologist/oncologist, Moffitt Cancer Center Magnolia Campus; Bradley D. Hunter, MD, medical director, Oncology, director, Immune Effector Cell Therapy, Intermountain Healthcare

Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD

ByBradley D. Hunter, MD, Onyee Chan, MD

December 24th 2024

Drs Chan and Hunter discuss asciminib in first-line CML, OPTIC trial data on ponatinib dosing, mutational testing, and stem cell transplant strategies.